NCT02866019View on ClinicalTrials.gov

Human (Autologous) Oral Mucosal Cell Sheet Transplantation After ESD in Patients With Superficial Esophageal Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Superficial Esophageal Cancer
Interventions
DEVICE

CLS2702C/CLS2702D

CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month \[4 weeks\]; cell sheet culture period, 0.5 month \[16 days\]; transplantation period, assessment/follow-up period, 6 months \[24 weeks\])

Trial Locations (3)

277-8577

National Cancer Center Hospital East, Kashiwa-shi

104-0045

National Cancer Center Hospital, Chuo-ku

162-8666

Tokyo Women's Medical University Hospital, Shinjuku-ku

Sponsors

Lead Sponsor

CellSeed Inc.
All Listed Sponsors
lead

CellSeed Inc.

INDUSTRY